Skip to main content
SpringerLink
Log in

Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro

  • Original Articles
  • In Vitro Cell Lines, Anthracyclines, Cross-resistance, Adriamycin
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Clinical resistance to adriamycin (ADR) develops readily, and cardiotoxicity is a major dose-limiting side effect. A range of anthracycline derivatives have been synthesized recently, and a number reported to exhibit significantly reduced cardiotoxicity in experimental animals. Using NIL 8 Syrian hamster overy cells and two continuous human tumour cell lines derived from colon carcinomas we have screened a series of 11 anthracycline analogues, determining their in vitro cytotoxic effects by colony-forming assays. Five agents proved significantly more cytotoxic than ADR: dihydroxyanthraquinone (DHAQ), mitoxantrone (DHAD), 4-demethoxydaunorubicin (4-DNR), 4′-0-tetrahydropyranyl-adriamycin (THP-ADR), and 4′-deoxyadriamycin (4-ADR). We have also established in vitro a subline of the L5178Y murine lymphoma resistant to ADR and have used this model to identify derivatives with potential value for overcoming ADR resistance. We have observed three patterns of response: (i) complete cross-resistance with 4′-epiadriamycin and daunorubicin; (ii) slight cross-resistance with 4-DNR, THP-ADR, 7-con-0-methyl-nogarol and aclacinomycin A; and (iii) complete absence of cross-resistance with 4-ADr, 4′-0-methyladriamycin, DHAQ, DHAD, and methylhydroxyellipticinium. These straightforward preclinical screens thus identify three drugs which may merit clinical evaluation, since they not only show an increased level of cytotoxicity in vitro to ADR at equivalent concentrations but also overcome resistance to ADR in this murine model system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson KC, Cohen GI, Garnick MB (1982) Phase II trial of mitoxantrone. Cancer Treat Rep 66:1929

    Google Scholar 

  2. Barfod MN (1977) Flow microfluorimetric estimation of G1 and G2 inhibition of the JB-1 tumour cell cycle in vitro. Exp Cell Res 110:225

    Google Scholar 

  3. Bargiotti A, Casazza AM, Cassinelli G, Di Marco A, Penco S, Pralesi G, Supino R, Zaccara A, Zunero F, Arcamone F (1983) Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moity. Cancer Chemother Pharmacol 10:84

    Google Scholar 

  4. Benjamin RS (1975) A practical approach to adriamycin (NSC-123127) toxicology. Cancer Chemother Rep 6:191

    Google Scholar 

  5. Berman E, Wittis RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6096

    Google Scholar 

  6. Bhuyan BK, Blowers CL, Crampton SL, Shugars KD (1981) Cell kill kinetics of several nogalamycin analogues and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture. Cancer Res 41:18

    Google Scholar 

  7. Carter SK, Livingston RB (1982) Drugs available to treat cancer: In: Carter SK, Glatstein E, Livingston RB (eds) Principles of cancer treatment. McGraw-Hill, New York, p 95

    Google Scholar 

  8. Casazza AM, Pratesi G, Giuliani F, DiMarco A (1980) Anti-leukemic activity of 4-demothoxy-daunorubicin in mice. Tumori 66:549

    Google Scholar 

  9. Cassinelli G, Ruggievi D, Arcamone F (1979) Synthesis and antitumour activity of 4′-0-methyldaunorubicin, 4′-0-methyladriamycin, and their 4′-epi analogues. J Med Chem 22:121

    Google Scholar 

  10. Clarysse A, Brugarolas A, Siegenthaler P, Abele R, Cavalli F, De Jager R, Renard G, Rozencweig M Hansen HH (1984) Phase II study of 9-hydroxy-2N-methylellipticinium acetate. Eur J Cancer Clin Oncol 20:243

    Google Scholar 

  11. Critchley DR, Chandrabose KA, Grahem JM, Macpherson I (1974) Glycolipids of NIL hamster cells as a function of cell density and cell cycle. In: Clarkson B, Baserga R (eds) Controls of proliferation in animal cells. Cold Spring Harbor Laboratories, Cold Spring Harbor, p 481

    Google Scholar 

  12. DiMarco A, Skovsgaard T, Casazza AM, Pratesi G, Nissen NI, Dano K (1981) Cross resistance and cellular uptake of 4′-0-methyldoxorubicin in experimental tumours with acquired resistance to doxorubicin. Cancer Chemother Pharmacol 7:15

    Google Scholar 

  13. Drewinko B, Shaver A, Yang LY (1978) Nutrient-dependent colony-forming capacity of cultured human colon carcinoma cells. Invest Cell Pathol 1:341

    Google Scholar 

  14. Drewinko B, Yang L-Y, Barlogie B, Trujillo JM (1983) Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro. Cancer Res 43:2648

    Google Scholar 

  15. Fujimoto S, Ogawa M (1982) Antitumour activity of mitoxantrone against murine experimental tumours: Comparative analysis against various antitumour antibiotics. Cancer Chemother Pharmacol 8:157

    Google Scholar 

  16. Giuliani FC, Kaplan NO (1980) New doxorubicin analogs active against doxorubicin-resistant colon tumour xenografts in the nude mouse. Cancer Res 40:4682

    Google Scholar 

  17. Giuliani FC, Coirin AK, Rice MR, Kaplan NO (1981) Effect of 4′-doxorubicin analogues on heterotransplantation of human tumours in congenitally athymic mice. Cancer Treat Rep 65:1063

    Google Scholar 

  18. Hill BT (1980) Lethal and kinetic effects of DDMP (2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine). Eur J Cancer 16:147

    Google Scholar 

  19. Hill BT, Whelan RDH (1982) Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivity. Cancer Chemother Pharmacol 8:163

    Google Scholar 

  20. Hill BT, Price LA, Goldie JH (1976) The value of adriamycin in overcoming resistance to methotrexate in tissue culture. Eur J Cancer 12:541

    Google Scholar 

  21. Hill BT, Whatley SA, Bellamy AS, Jenkins LY, Whelan RDH (1982) Cytotoxic effects and biological activity of 2-aza-8-germanspiro [4,5]-decane-2-propanamine-8,8-diethyl-N,M-dimethyl dichloride (NCS192965: spirogermanium) in vitro. Cancer Res 42:2852

    Google Scholar 

  22. Hubbard SM, Barkes P, Young R (1978) Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep 62:1375

    Google Scholar 

  23. Inoue K, Arakawa M, Miyamoto H, Ogawa M (1983) Activity of 4′-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumour cloning system. Invest New Drugs 1:271

    Google Scholar 

  24. Johnson RK, Chitnis MP, Embrey WM, Gregory EB (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline P388 leukemia. Cancer Treat Rep 62:1534

    Google Scholar 

  25. Johnson RK, Broome MG, Howard WS, Evans SF, Pritchard DF (1983) Experimental therapeutic and biochemical studies of anthracenedione derivatives: In Rozencweig M, Von Hoff DD, Staquet MD (eds) New anticancer drugs: Mitoxantrone and bisantrene. Raven, New York, p 1 (Monograph series of the European Organization for Research on Treatment of Cancer, vol 12)

    Google Scholar 

  26. Karanes C, Young JB, Smason KK, Smith LB, Franco LA, Baker LH (1983) Phase I trial of aclacinomycin-A. Invest New Drugs 1:173

    Google Scholar 

  27. Kimler BF, Cheng CC (1982) The comparison of the effects of dihydroxyanthraquinone and adriamycin of the survival of cultured Chinese hamster cells. Cancer Res 42:3631

    Google Scholar 

  28. Minna JD, Carney DN, Cuttitta F, Gazdar AF (1983) The biology of lung cancer: In: Chabner BA (ed) Rational basis for chemotherapy. Liss, New York, p 1

    Google Scholar 

  29. Minow RA, Benjamin RS, Gottlieb JA (1975) Adriamycin (NSC123127) cardiomyopathy — an overview with determination of risk factors. Cancer Chemother Rep 6:195

    Google Scholar 

  30. Muggia FM, Rozencweig M (1983) The anthracycline antibiotics: New directions in drug development and cancer treatment. In: Muggia FM (ed) Cancer chemotherapy, no 1. Nijhoff, The Hague, p 123

    Google Scholar 

  31. Ogawa M, Miyamoto H, Inigaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H (1983) Phase I clinical trial of a new anthracycline: 4′-0-tetrahydropyranyl adriamycin. Invest New Drugs 1:169

    Google Scholar 

  32. Robustelli Della Cuna G, Pervase K, Preti P, Ganzina F (1983) Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumours. Invest New Drugs 1:349

    Google Scholar 

  33. Rozencweig M, Crespeigne N, Kenis Y (1983) Phase I trial with 4′-deoxydoxorubicin (esorubicin). Invest New Drugs 1:309

    Google Scholar 

  34. Salmon SE, Liu RM, Casazza AM (1981) Evaluation of new anthracycline analogs with the human tumour stem cell assay. Cancer Chemother Pharmacol 6:103

    Google Scholar 

  35. Schwartz HS, Kanter PM (1979) Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents. Cancer Treat Rep 63:821

    Google Scholar 

  36. Scott JP, Fraccastora AP, Taft EB (1965) Studies in histochemistry: I. Determination of nucleic acids in microgram amounts of tissue. J Histochem Cytochem 4:1

    Google Scholar 

  37. Semple TV, Quinn LA, Woods LK, Moore GE (1978) Tumour and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res 38:3145

    Google Scholar 

  38. Taetle R, Howell SB, Giuliani FC, Koziol J, Koesler A (1982) Comparison of the activity of doxorubicin analogues using colony-forming assays and human xenografts. Cancer 50:145

    Google Scholar 

  39. Tihon C, Issell BF (1982) Activity of anthracyclines on human tumours in vitro: In: Muggia FM, Young CW, Carter SK (eds) Anthracycline antibiotics in cancer therapy. Nijhoff, The Hague, p 247

    Google Scholar 

  40. Traganos F, Staiano-Coico L, Darzynkiewicz Z, Melamed MR (1981) Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells. Cancer Res 41:2728

    Google Scholar 

  41. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4′-0-tetrahydropyranyl-adriamycin as a potential new antitumour agent. Cancer Res 42:1462

    Google Scholar 

  42. Von Hoff DD (1982) Screening the second-generation anthracyclines in a human tumour cloning system: In: Muggia FM, Young CW, Carter SK (eds) Anthracyclines antibiotics in cancer therapy. Nijhoff, The Hague, p 240

    Google Scholar 

  43. Von Hoff DD, Coltman CA, Forseth B (1981) Activity of mitoxantrone in a human tumour cloning system. Cancer Res 41:1853

    Google Scholar 

  44. Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WT, Carter SK (1975) Tabular analysis of the clinical chemotherapy of solid tumours. Cancer Chemother Rep 6:399

    Google Scholar 

  45. Zirvi KA, Van der Bosch J, Kaplin NO (1982) In vitro responses of nude mouse-xenografted human carcinomas exposed to doxorubicin derivatives in tissue culture and in the mouse. Cancer Res 42:3793

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cellular Chemotherapy, Imperial Cancer Research Fund, Lincoln's Inn Fields, WC2A 3PX, London, England

    Bridget T. Hill, Lorraine Y. Dennis, Xue-Teng Li & Richard D. H. Whelan

Authors
  1. Bridget T. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorraine Y. Dennis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xue-Teng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard D. H. Whelan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hill, B.T., Dennis, L.Y., Li, XT. et al. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother. Pharmacol. 14, 194–201 (1985). https://doi.org/10.1007/BF00258115

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00258115

Keywords

Search

Navigation